DPSCs, as emerging “immunomodulators”, can effectively inhibit the activation of T and B cells and regulate the Fas/FasL apoptotic pathway, which has been shown to be a potentially effective treatment for SS. The gene discussed is FASLG; the disease is synovial sarcoma.